870701-97-6

Upstream product

• 21085-72-3 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester 
• 148579-94-6 (25,3R,45,55,65)-2-(4-(hydroxymethyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 148579-93-5 (2S,3R,4S,5S,6S)-2-(4-formyl-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 870701-96-5 methyl 1-(4-(2-hydroxyethylcarbamoyloxymethyl)-2-nitrophenyl)-2,3,4-tri-O-acetyl-β-D-glucopyronuronate 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 866611-65-6 (2S,3R,4S,5S,6S)-2-(4-(((1H-imidazole-1-carbonyl)oxy)methyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 

Relevant academic research and scientific papers

Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase

The present invention relates to magnetic resonance imaging (MRI) contrast agent. In particular, the present invention provides MRI contrast agents that are sensitive to the enzyme beta-glucoronidase. The MRI contrast agents provide compositions and methods for non-invasive diagnostic imaging of tissues, including necrotic tumors.

A gadolinium chelate for detection of β-glucuronidase: A self-immolative approach

New classes of physiologically responsive magnetic resonance (MR) contrast agents are being developed that are activated by enzymes, secondary messengers, pH, and temperature. To this end, we have prepared a new class of enzyme-activated MR contrast agent